AstraZeneca Plc's COVID19 vaccine trial in the United States is expected to resume as early as this week after the U.S. Food and Drug Administration completed its review of a serious illness in a study participant, four sources told Reuters. from Top Business News- News18.com Read The Rest:timesnownews...
No comments: